The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)
The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized with the cases in which the disease has progressed during or after platinum-based chemotherapy.
The drug - JNJ-6372 – targets activating and resistant EGFR and MET (mesenchymal epithelial transition factor) mutations and amplifications, is an EGFR-MET bispecific antibody. At present, there exists no therapy that targets the EGFR Exon 20 insertion mutations i...
